RT Journal Article
SR Electronic
T1 Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257122
DO 10.1101/2021.05.17.21257122
A1 Kotwa, Jonathon D.
A1 Jamal, Alainna J.
A1 Mbareche, Hamza
A1 Yip, Lily
A1 Aftanas, Patryk
A1 Barati, Shiva
A1 Bell, Natalie G.
A1 Bryce, Elizabeth
A1 Coomes, Eric
A1 Crowl, Gloria
A1 Duchaine, Caroline
A1 Faheem, Amna
A1 Farooqi, Lubna
A1 Hiebert, Ryan
A1 Katz, Kevin
A1 Khan, Saman
A1 Kozak, Robert
A1 Li, Angel X.
A1 Mistry, Henna P.
A1 Mozafarihashjin, Mohammad
A1 Nasir, Jalees A.
A1 Nirmalarajah, Kuganya
A1 Panousis, Emily M.
A1 Paterson, Aimee
A1 Plenderleith, Simon
A1 Powis, Jeff
A1 Prost, Karren
A1 Schryer, Renée
A1 Taylor, Maureen
A1 Veillette, Marc
A1 Wong, Titus
A1 Zhong, Xi Zoe
A1 McArthur, Andrew G.
A1 McGeer, Allison J.
A1 Mubareka, Samira
YR 2021
UL http://medrxiv.org/content/early/2021/06/19/2021.05.17.21257122.abstract
AB Background The aim of this prospective cohort study was to determine the burden of SARS-CoV-2 in air and on surfaces in rooms of patients hospitalized with COVID-19, and to identify patient characteristics associated with SARS-CoV-2 environmental contamination.Methods Nasopharyngeal swabs, surface, and air samples were collected from the rooms of 78 inpatients with COVID-19 at six acute care hospitals in Toronto from March to May 2020. Samples were tested for SARS-CoV-2 viral RNA and cultured to determine potential infectivity. Whole viral genomes were sequenced from nasopharyngeal and surface samples. Association between patient factors and detection of SARS-CoV-2 RNA in surface samples were investigated using a mixed-effects logistic regression model.Findings SARS-CoV-2 RNA was detected from surfaces (125/474 samples; 42/78 patients) and air (3/146 samples; 3/45 patients) in COVID-19 patient rooms; 17% (6/36) of surface samples from three patients yielded viable virus. Viral sequences from nasopharyngeal and surface samples clustered by patient.Multivariable analysis indicated hypoxia at admission, a PCR-positive nasopharyngeal swab with a cycle threshold of ≤30 on or after surface sampling date, higher Charlson co-morbidity score, and shorter time from onset of illness to sample date were significantly associated with detection of SARS-CoV-2 RNA in surface samples.Interpretation The infrequent recovery of infectious SARS-CoV-2 virus from the environment suggests that the risk to healthcare workers from air and near-patient surfaces in acute care hospital wards is likely limited. Surface contamination was greater when patients were earlier in their course of illness and in those with hypoxia, multiple co-morbidities, and higher SARS-CoV-2 RNA concentration in NP swabs. Our results suggest that air and surfaces may pose limited risk a few days after admission to acute care hospitals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Canadian Institutes of Health Research (CIHR No. RN419944-439999) as well as Genome Canada CanCOGeN funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics approval was granted by all participating The Toronto Invasive Bacterial Diseases Network hospitals (Sunnybrooks Research Ethics Board, The Mount Sinai Hospital Research Ethics Board, Toronto East Health Network Research Ethics Board, Oslers Research Ethics Board, and Scarborough Health Networks Research Ethics Board).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, SM, upon reasonable request.